Today’s Arthritis Olympics Challenge: Go bicycling! To follow the Canadian Paralympic Team’s progress, please visit the CBC’s Paralympics page here.
Did you know?
Olympian speed skater Kristine Holzer had juvenile rheumatoid arthritis since the young age of 13. Kristine wanted to remain active and chose to participate in low impact sports like rowing and speed skating. She was second place at the 1998 United States Senior National Team Trials. When she did not get the spot to compete in the 1998 World Rowing Championships, she started her training to become a speed skater at the age of 24. She attended the 2006 Winter Olympic Games and earned 27th place in the 3000 meters and placed fifth place with team USA in the women’s Team Pursuit.
Olympian Kristin Armstrong was diagnosed with osteoarthritis in her hips in 2001 at age 28. She used cycling as a way to manage her arthritis and stay active with her arthritis. She accomplished her greatest athletic moments after her diagnosis, including three world championship medals and a gold medal at the 2008 Olympics in Beijing and the 2012 Olympics in London.
BC PharmaCare is looking for your input on tocilizumab for the treatment of polyarticular juvenile idiopathic arthritis (pJIA).
Tocilizumab (Actemra®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about tocilizumab for the treatment of polyarticular juvenile idiopathic arthritis (pJIA)
You can give input if you are a B.C. resident and have pJIA, a caregiver to someone with pJIA, or if your group represents people who live with pJIA. Continue reading
Last October, the U.S. Food and Drug Administration (FDA) approved Otrexup, a single-dose auto-injector containing methotrexate (MTX) to treat rheumatoid arthritis (RA) and psoriasis in adults, and polyarticular idiopathic arthritis (pJIA) in children. Otrexup is taken once a week via self-administration with an easy-to-use, single dose, and disposable auto injector. Antares Pharma have announced the availability of Otrexup in their company.
When asked for his thoughts on Otrexup, Seth Ginsberg, President and Co-founder of CreakyJoints, said: “CreakyJoints welcomes new treatment options for patients with RA. Because so many RA patients have limited manual dexterity, conventional syringes for injection of methotrexate with a pre-filled auto-injector is an important edition to treatment options available because it expands RA patients’ access to care.” Continue reading
Only 20 more days to Christmas holiday! This is a great time to think back on the year and thank those who have helped the arthritis community. To list a few of many, we think the following organizations have made it to Santa’s “Nice List”. Do you know of any accomplishment(s) by an individual, community group, or organization that have shown great care and support to the arthritis community this year? If you do, please share with everyone in the comments section. Alternatively, you may share via our Facebook and Twitter channel with hashtag #ACESantaList.
Arthritis Consumer Experts’ “ACE Santa’s Nice List” Continue reading
Health Canada approves tocilizumab (Actemra®) to treat Canadian children with polyarticular juvenile idiopathic arthritis.
Nearly two years ago tocilizumab (Actemra®) was approved by Health Canada for treating the systemic form of juvenile idiopathic arthritis (JIA). One week ago that approval was expanded to include polyarticular-course JIA. Continue reading
Tocilizumab (Actemra®) approved in Prince Edward Island for the treatment of systemic juvenile idiopathic arthritis AND rheumatoid arthritis.
On October 1st, tocilizumab (Actemra®) became listed on Prince Edward Island’s medication formulary, under the newly established Catastrophic Drug Program, for the treatment of systemic juvenile idiopathic arthritis (sJIA) and rheumatoid arthritis (RA).
Tocilizumab belongs to the class of medications called “biologics” (short for biologic response modifiers), which target the specific pathways responsible for causing inflammation and joint destruction. Tocilizumab specifically inhibits or slows down the body’s production of IL-6 (a protein that when overproduced promotes inflammation) and is effective at treating the symptoms and underlying disease process in sJIA and RA.
We commend the province for adding tocilizumab because now children with sJIA and adults with RA who live in PEI will have a treatment option where none in this class of medication existed for them before. Since everyone responds differently to the available medications, no single biologic therapy is effective for treating RA or sJIA. The addition of tocilizumab means one more treatment option is available for residents of PEI, and that improves the chances of finding the right one for an individual.
The change is reflected in October’s update of the JointHealth™ Report Card on provincial formulary reimbursement listings for biologic response modifiers.